Sirona Biochem Corp
XTSX:SBM
We don't have any information about SBM's insider trading.
Sirona Biochem Corp
Glance View
Sirona Biochem Corp. engages in development of cosmetic ingredient and drug. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2007-07-10. The firm developed its technology platform at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. Its principal activities are dedicated to the development of cosmetic and pharmaceutical active ingredients which are partners in exchange for payments. The Company’s marketed products include SGLT2 Inhibitor, TFC-1067 and Anti-Aging/ Anti-Wrinkle. SGLT2 Inhibitors is a therapy for diabetes treatments. SGLT2 Inhibitors act in the kidneys to reduce the re-absorption of glucose into the bloodstream. The firm has developed an ingredient, TFC-1067 for the treatment of Dyschromia. The firm through its subsidiary, TFChem, has developed Anti-Aging/ Anti-Wrinkle. The firm through its platform technology, produce therapies in three antiviral categories, Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars.
What is Insider Trading?
Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.
While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.
Why is Insider Trading Important?
It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.
However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
